Text Size
|
Knoxville, Tenn., March 5, 2010 – PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. announced today that it is prepared to distribute, on a national basis, 18F-sodium fluoride (18F-NaF) through its network of 47 PET radiopharmacies in the U.S.
In support of the February 26 CMS memorandum to allow for Coverage with Evidence Development (CED) of 18F-NaF PET imaging to identify bone metastases of cancer to inform the initial antitumor treatment strategy or to guide subsequent antitumor treatment strategy after the completion of initial treatment, PETNET Solutions is prepared to distribute 18F-NaF as the demand increases.
18F-NaF is an FDA-approved imaging agent and is used in the detection of bone metastases. CMS reimbursement support of the imaging agent could provide the medical community with alternatives to Tc-99m-labeled diphosphonate agents, in particular, during the ongoing global shortage of Mo-99/Tc-99m generators. It also leverages Siemens’ biomarker technology and PETNET Solutions as the industry’s largest network of PET biomarker production facilities.
The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2009 (to September 30), the Sector posted revenue of 11.9 billion euros and profit of around 1.5 billion euros. For further information please visit: www.siemens.com/healthcare.
Text Size
|
